Estimating 2-year risk of first relapse in ANCA-associated vasculitis: derivation of a risk-prediction model based on participants in the PEXIVAS trial
Annals of the Rheumatic Diseases · 2026-11 · 85 (11) · 2233-2240
DOI: 10.1016/j.ard.2026.08.020 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Annals of the Rheumatic Diseases, 2026-11. Verfasst von Mats Junek und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, McMaster University, Hamilton, ON, Canada; Department of Health Research Methods, Evidence and Impact, McMaster University, H…. Hauptthemen laut MEDLINE: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis. Die Arbeit nennt 34 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVES: Individuals with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) differ in their risk of relapse. Estimation of an individual's risk may inform decision-making around monitoring and treatment. METHODS: We performed a post hoc analysis of participants with AAV with an estimated glomerular filtration rate (eGFR)
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, McMaster University, Hamilton, ON, Canada; Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada. Electronic address: junekm@mcmaster.ca.
- Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada.
- Division of Rheumatology, Department of Medicine, Division of Epidemiology, Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, PA, USA.
- Department of Medicine, John Hunter Hospital, NSW, Australia.
- Department of Medicine, St Michael's Hospital, Toronto, ON, Canada.
- Division of Nephrology, Department of Medicine, University of Ottawa, Ottawa, ON, Canada.
Zitieren
APA
Junek, M., Ibrahim, Q., Merkel, P. A., Vilayur, E., Wald, R., Fairhead, T., Massicotte-Azarniouch, D., Girard, L., Pagnoux, C., Khalidi, N., Jayne, D., Walsh, M., & PEXIVAS investigators (2026). Estimating 2-year risk of first relapse in ANCA-associated vasculitis: derivation of a risk-prediction model based on participants in the PEXIVAS trial. Annals of the Rheumatic Diseases, 85(11), 2233-2240. https://doi.org/10.1016/j.ard.2026.08.020
Vancouver
Junek M, Ibrahim Q, Merkel PA, Vilayur E, Wald R, Fairhead T, et al. Estimating 2-year risk of first relapse in ANCA-associated vasculitis: derivation of a risk-prediction model based on participants in the PEXIVAS trial. Annals of the Rheumatic Diseases. 2026;85(11):2233-2240. doi:10.1016/j.ard.2026.08.020
BibTeX
@article{Junek2026,
author = {Junek, Mats and Ibrahim, Quazi and Merkel, Peter A and Vilayur, Eswari and Wald, Ron and Fairhead, Todd and Massicotte-Azarniouch, David and Girard, Louis and Pagnoux, Christian and Khalidi, Nader and Jayne, David and Walsh, Michael and PEXIVAS investigators, PEXIVAS investigators},
title = {Estimating 2-year risk of first relapse in ANCA-associated vasculitis: derivation of a risk-prediction model based on participants in the PEXIVAS trial},
journal = {Annals of the Rheumatic Diseases},
year = {2026},
volume = {85},
number = {11},
pages = {2233--2240},
doi = {10.1016/j.ard.2026.08.020}
}
EUVIMED